$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000114420418026625 Filed on May 09, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$4.553M	$2.889M
YoY Change	57.6%	325.48%
Cost Of Revenue	$2.924M	$2.088M
YoY Change	40.04%	299.24%
Gross Profit	$1.629M	$801.0K
YoY Change	103.37%	413.46%
Gross Profit Margin	35.78%	27.73%
Selling, General & Admin	$2.498M	$2.537M
YoY Change	-1.54%	27.17%
% of Gross Profit	153.35%	316.73%
Research & Development	$7.286M	$5.967M
YoY Change	22.1%	-18.64%
% of Gross Profit	447.27%	744.94%
Depreciation & Amortization	$430.0K	$492.0K
YoY Change	-12.6%	-4.65%
% of Gross Profit	26.4%	61.42%
Operating Expenses	$9.784M	$8.504M
YoY Change	15.05%	-8.84%
Operating Profit	-$5.151M	-$6.365M
YoY Change	-19.07%	-19.06%
Interest Expense	-$2.090M	-$52.78M
YoY Change	-96.04%	7896.97%
% of Operating Profit
Other Income/Expense, Net	-$2.088M	-$52.78M
YoY Change	-96.04%	7873.26%
Pretax Income	-$7.240M	-$59.15M
YoY Change	-87.76%	593.43%
Income Tax
% Of Pretax Income
Net Earnings	-$7.239M	-$59.15M
YoY Change	-87.76%	587.93%
Net Earnings / Revenue	-158.99%	-2047.35%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.50	-$4.75
COMMON SHARES
Basic Shares Outstanding		124.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.30M	$48.00M
YoY Change	-13.96%	-28.04%
Cash & Equivalents	$41.32M	$48.02M
Short-Term Investments
Other Short-Term Assets	$2.600M	$3.700M
YoY Change	-29.73%	-5.13%
Inventory	$7.000M	$7.100M
Prepaid Expenses
Receivables	$4.756M	$2.737M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$55.69M	$61.50M
YoY Change	-9.45%	-19.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.311M	$8.500M
YoY Change	-13.99%	-8.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.800M	$1.800M
YoY Change	0.0%	5.88%
Total Long-Term Assets	$9.109M	$10.40M
YoY Change	-12.41%	-5.45%
TOTAL ASSETS
Total Short-Term Assets	$55.69M	$61.50M
Total Long-Term Assets	$9.109M	$10.40M
Total Assets	$64.80M	$71.90M
YoY Change	-9.88%	-17.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.900M	$6.000M
YoY Change	-18.33%	53.85%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.900M	$0.00
YoY Change
Total Short-Term Liabilities	$21.50M	$20.30M
YoY Change	5.91%	118.28%
LONG-TERM LIABILITIES
Long-Term Debt	$51.30M	$117.5M
YoY Change	-56.34%	62.74%
Other Long-Term Liabilities	$5.172M	$2.500M
YoY Change	106.88%	-21.88%
Total Long-Term Liabilities	$82.74M	$120.0M
YoY Change	-31.05%	59.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.50M	$20.30M
Total Long-Term Liabilities	$82.74M	$120.0M
Total Liabilities	$104.2M	$140.3M
YoY Change	-25.7%	65.64%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$35.44M	-$68.50M
YoY Change
Total Liabilities & Shareholders Equity	$64.80M	$71.90M
YoY Change	-9.88%	-17.64%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$7.239M	-$59.15M
YoY Change	-87.76%	587.93%
Depreciation, Depletion And Amortization	$430.0K	$492.0K
YoY Change	-12.6%	-4.65%
Cash From Operating Activities	-$9.413M	-$8.426M
YoY Change	11.71%	-12.46%
INVESTING ACTIVITIES
Capital Expenditures	$249.0K	$220.0K
YoY Change	13.18%	-12.35%
Acquisitions
YoY Change
Other Investing Activities	-$109.0K	$40.00K
YoY Change	-372.5%	-4.76%
Cash From Investing Activities	-$328.0K	-$283.0K
YoY Change	15.9%	-3.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-$6.726M
YoY Change
NET CHANGE
Cash From Operating Activities	-9.413M	-$8.426M
Cash From Investing Activities	-328.0K	-$283.0K
Cash From Financing Activities		-$6.726M
Net Change In Cash	-9.741M	-$15.44M
YoY Change	-36.89%	55.63%
FREE CASH FLOW
Cash From Operating Activities	-$9.413M	-$8.426M
Capital Expenditures	$249.0K	$220.0K
Free Cash Flow	-$9.662M	-$8.646M
YoY Change	11.75%	-12.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	us-gaap	Assets Current AssetsCurrent	55688000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	62651000	USD
CY2018Q1	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1798000	USD
CY2017Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1887000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7311000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7676000	USD
CY2018Q1	us-gaap	Assets Assets	64797000	USD
CY2017Q4	us-gaap	Assets Assets	72214000	USD
CY2018Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4872000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7521000	USD
CY2018Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	10697000	USD
CY2017Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	9310000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	21499000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22752000	USD
CY2018Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	46108000	USD
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	46267000	USD
CY2018Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2427000	USD
CY2017Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2586000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	103507000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64797000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72214000	USD
CY2018Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	82737000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	80755000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	104236000	USD
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5921000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1721000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4756000	USD
CY2018Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5930000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5172000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5051000	USD
CY2018Q1	us-gaap	Revenues Revenues	4553000	USD
CY2017Q1	us-gaap	Revenues Revenues	2889000	USD
CY2018Q1	us-gaap	Cost Of Revenue CostOfRevenue	2924000	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	2088000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	1629000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	801000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7286000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5967000	USD
CY2018Q1	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	6443000	USD
CY2017Q1	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	4629000	USD
CY2018Q1	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	843000	USD
CY2017Q1	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1338000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2498000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2537000	USD
CY2017Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-52321000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-9957000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	118000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-39439000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46000	USD
CY2018Q1	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	16000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1192000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-9400000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	62000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	118000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	430000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1088000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3512000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3092000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1855000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1009000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	220000	USD
CY2017Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	23000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-109000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15264000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63281000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48017000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8426000	USD
CY2018Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	188000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2179000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-814000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	619000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	590000	USD
CY2018Q1	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	-124000	USD
CY2017Q1	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	42000	USD
CY2018Q1	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	44000	USD
CY2017Q1	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	20000	USD
CY2018Q1	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	342000	USD
CY2017Q1	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	636000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	145000	USD
CY2017Q1	us-gaap	Interest Paid Net InterestPaidNet	432000	USD
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	78142133	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	73800491	shares
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3838000	USD
CY2018Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3529000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3510000	USD
CY2018Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3173000	USD
CY2018Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	317000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	485000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-31293000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	517000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q1	plx	Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes	205000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9413000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	29030000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	26851000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	121000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9413000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8548000	USD
CY2018Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		USD
CY2017Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	122000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-328000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-283000	USD
CY2017Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	6726000	USD
CY2018Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	987000	USD
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	517000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6726000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-103000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	171000	USD
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Protalix BioTherapeutics, Inc.
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Trading Symbol TradingSymbol	PLX
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	145569955	shares
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2018Q1	plx	Income Loss On Conversion Of Convertible Notes IncomeLossOnConversionOfConvertibleNotes	-218000	USD
CY2017Q1	plx	Income Loss On Conversion Of Convertible Notes IncomeLossOnConversionOfConvertibleNotes	1445000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	145305982	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	124467602	shares

Files In Submission

Name	View Source	Status
0001144204-18-026625-index-headers.html	Edgar Link	pending
0001144204-18-026625-index.html	Edgar Link	pending
0001144204-18-026625.txt	Edgar Link	pending
0001144204-18-026625-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
plx-20180331.xml	Edgar Link	completed
plx-20180331.xsd	Edgar Link	pending
plx-20180331_cal.xml	Edgar Link	unprocessable
plx-20180331_def.xml	Edgar Link	unprocessable
plx-20180331_lab.xml	Edgar Link	unprocessable
plx-20180331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv492512_10q.htm	Edgar Link	pending
tv492512_ex31-1.htm	Edgar Link	pending
tv492512_ex31-2.htm	Edgar Link	pending
tv492512_ex32-1.htm	Edgar Link	pending
tv492512_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2018 Q1 Form 10-Q Financial Statement

#000114420418026625 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2018 Q1 Form 10-Q Financial Statement

#000114420418026625 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx